Savara Inc（SVRA）資訊與事件SVRASavara Inc

Savara Presents IMPALA-2 Trial Data at ERS Congress in Barcelona

Savara announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026. "Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may normalize the underlying pathobiology," said Bruce C. Trapnell, M.D., Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine and the Lead Clinical Investigator of the IMPALA-2 clinical trial. "Combined with the high retention rate in the trial and durability of effect we've now seen through the first 48-weeks of the IMPALA-2 open-label period, these results strongly support molgramostim's potential as an effective long-term option for a patient population with no approved pharmacologic treatments. We look forward to sharing these data at the ERS Congress."

Savara CEO Highlights U.S. Launch Opportunity for MOLBREEVI

"While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term opportunity," said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara. "Our focus is on the potential launch of MOLBREEVI in the U.S., supported by a strong balance sheet to ensure commercial readiness."

Savara Secures Patent for Molbreevi Liquid Formulation

Savara announced that the European Patent Office, EPO, has granted a patent covering the liquid formulation of Molbreevi, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor. European patent No.4121000 provides protection for Molbreevi through March 2041. Separately, the Australian Patent Office has also granted a patent covering the liquid formulation of Molbreevi, and securing protection in Australia through the same date. "These patents further strengthen the Company's intellectual property portfolio for Molbreevi, providing an additional layer of defense in markets with no approved alternatives," said Kate McCabe, Chief Legal Officer, Savara. "Together, these patents reflect the strength of our liquid formulation IP across key ex-US markets. In parallel, we are advancing equivalent patent filings in the U.S., including a patent for the drug-device combination, with the aim of securing comprehensive protection across major commercial territories."